Next Article in Journal
Emotional Intelligence and Professional Boredom among Nursing Personnel in Greece
Previous Article in Journal
“My Patients Asked Me If I Owned a Fruit Stand in Town or Something.” Barriers and Facilitators of Personalized Dietary Advice Implemented in a Primary Care Setting
Previous Article in Special Issue
Predictive Biomarkers of Oxaliplatin-Induced Peripheral Neurotoxicity
Article

LAG-3 Expression Predicts Outcome in Stage II Colon Cancer

1
Department of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland
2
Department of Medical Oncology, HFR Fribourg Hospital, 1708 Fribourg, Switzerland
3
Division of Pathology and Lab Medicine, University of Toronto, Toronto, ON M5G 1X5, Canada
4
Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, MD 21212, USA
5
Institute of Pathology, University of Bern, 3008 Bern, Switzerland
*
Author to whom correspondence should be addressed.
Academic Editors: Enrico Mini and Stefania Nobili
J. Pers. Med. 2021, 11(8), 749; https://doi.org/10.3390/jpm11080749
Received: 16 July 2021 / Accepted: 20 July 2021 / Published: 30 July 2021
(This article belongs to the Special Issue Gastrointestinal Cancers and Personalized Medicine)
Introduction: LAG-3 is an inhibitory immune checkpoint molecule that suppresses T cell activation and inflammatory cytokine secretion. T cell density in the tumor microenvironment of colon cancer plays an important role in the host’s immunosurveillance. We therefore hypothesized that LAG-3 expression on tumor-infiltrating lymphocytes (TILs) predicts outcome in patients with stage II colon cancer. Patients and Methods: Immunohistochemical staining for LAG-3 was performed on tissue microarrays (TMAs) of formalin-fixed paraffin-embedded tissue from 142 stage II colon cancer patients. LAG-3 expression was assessed in TILs within both the tumor front and tumor center and scored as either positive or negative. The primary endpoint was disease-free survival (DFS). Results: In patients diagnosed with stage II colon cancer, the presence of LAG-3 expression on TILs was significantly associated with better 5-year DFS (HR 0.34, 95% CI 0.14–0.80, p = 0.009). The effect on DFS was mainly due to LAG-3-positive TILs in the tumor front (HR 0.33, 95% CI 0.13–0.82, p = 0.012). Conclusion: Assessment of LAG-3 might help to predict outcomes in patients with stage II colon cancer and potentially identify those patients who might benefit from adjuvant chemotherapy. Therefore, LAG-3 may serve as a prognostic biomarker in stage II colon cancer. View Full-Text
Keywords: biomarker; LAG-3; immune checkpoint; colon cancer; survival biomarker; LAG-3; immune checkpoint; colon cancer; survival
Show Figures

Figure 1

MDPI and ACS Style

Rhyner Agocs, G.; Assarzadegan, N.; Kirsch, R.; Dawson, H.; Galván, J.A.; Lugli, A.; Zlobec, I.; Berger, M.D. LAG-3 Expression Predicts Outcome in Stage II Colon Cancer. J. Pers. Med. 2021, 11, 749. https://doi.org/10.3390/jpm11080749

AMA Style

Rhyner Agocs G, Assarzadegan N, Kirsch R, Dawson H, Galván JA, Lugli A, Zlobec I, Berger MD. LAG-3 Expression Predicts Outcome in Stage II Colon Cancer. Journal of Personalized Medicine. 2021; 11(8):749. https://doi.org/10.3390/jpm11080749

Chicago/Turabian Style

Rhyner Agocs, Gaëlle, Naziheh Assarzadegan, Richard Kirsch, Heather Dawson, José A. Galván, Alessandro Lugli, Inti Zlobec, and Martin D. Berger 2021. "LAG-3 Expression Predicts Outcome in Stage II Colon Cancer" Journal of Personalized Medicine 11, no. 8: 749. https://doi.org/10.3390/jpm11080749

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop